Straits Times Index
3,280.10 -7.65 (-0.23%) Nikkei
37,934.76 +306.28 (+0.81%) Hang Seng
17,651.15 +366.61 (+2.12%) FTSE 100
8,139.83 +60.97 (+0.75%) Bitcoin USD
62,997.41 -1,344.56 (-2.09%) CMC Crypto 200
1,304.48 -92.06 (-6.59%)
REGN Dec 2025 600.000 call
| Previous close | 371.10 |
| Open | 371.10 |
| Bid | 347.00 |
| Ask | 356.00 |
| Strike | 600.00 |
| Expiry date | 2025-12-19 |
| Day's range | 371.10 - 371.10 |
| Contract range | N/A |
| Volume | |
| Open interest | 5 |
ZacksEXEL vs. REGN: Which Stock Is the Better Value Option?
EXEL vs. REGN: Which Stock Is the Better Value Option?
ZacksRegeneron (REGN) Reports Next Week: What You Should Expect
Regeneron (REGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Reuters
UPDATE 1-AbbVie's skin disease drug found to be more effective than Regeneron's Dupixent in study
AbbVie said on Thursday its drug, Rinvoq, for treating a type of inflammatory skin condition was found to be more effective than Regeneron Pharmaceuticals and Sanofi's Dupixent in a late-stage head-to-head study. Rinvoq helped 19.9% of patients simultaneously achieve near-complete skin clearance with a no-to-little itch after 16 weeks of treatment, compared with 8.9% of patients treated with Dupixent, the study showed. The study is the first head-to-head trial in adults and adolescents with moderate-to-severe atopic dermatitis and had shown an inadequate response to systemic therapy, AbbVie said.
